Bjornsti et al., 1989, “Expression of Human DNA Topoisomerase I in Yeast Cells Lacking Yeast DNA Topoisomerase I:Restoration of Sensitivity of the Cells to the Antitumor Drug Camptothecin ”, Cancer Res. 49:6318-6323. |
Bjornsti and Wang, 1987, “Expression of Yeast DNA Topoisomerase I Can Complement a Conditional—Lethal DNA Topoisomerase I Mutation in Escherichia coli ”, Proc. Natl. Acad. USA 84:8971-8975. |
Chen et al., 1984 “Nonintercalative Antitumor Drugs Interfere with the Breakage-Reunion Reaction of Mammalian DNA Topoisomerase II ”, J. Biol. Chem. 259:13560-13566. |
DiNardo et al., 1982 “Escherichia coli DNA Topoisomerase I Mutants Have Compensatory Mutations in DNA Gyrase Genes”, Cell 31:43-51. |
Dorman et al., 1989 “DNA Supercoiling in Escherichia coli: topA Mutations Can Be Suppressed by DNA Amplifications Involving the tolC Locus ”, Molec. Microbiol. 3:531-540. |
Drlica and Zhao, 1997, “DNA Gyrase, Topoisomerase IV and the 4-Quinolones”, Microbiol. Mol. Biol. Rev.61:377-392. |
Drlica and Franco, 1988, “Inhibitors of DNA Topoisomerases”, Biochem. 27:2253-2259. |
Drolet et al., 1995, “Overexpression of Rnase H Partially Complements the Growth Defect of an Escherichia coli ΔtopA Mutant: R-Loop Formation is Major Problem in the Absence of DNA Topoisomerase I ”, Proc. Natl. Acad. Sci. USA 92:3526-3530. |
Huisman and D'Ari, 1981, “An Inducible DNA Replication-Cell Division Coupling Mechanism in E. coli”, Nature 290:797-799. |
Kenyon et al., 1982, “Regulation of Damage-Inducible Genes in Escherichia coli ”, J. Mol. Biol. 160:445-457. |
Liu, 1990, “Anticancer Drugs that Convert DNA Topoisomerases into DNA Damaging Agents”, in: DNA Toplology and Its Biolgical Effects, Cozzarelli and Wang, eds., Cold Spring Harbor Press, pp. 371-389. |
Mamber et al., 1990, “Induction of the SOS Response in Escherichia coli by Azidothymidine and Dideoxynucleosides”, Antimicrobial Agents and Chemother. 34:1237-1243. |
Nitiss and Wang, 1988, “DNA Topoisomerase-Targeting Antitumor Drugs Can Be Studied in Yeast”, Proc. Natl. Acad. Sci. USA 85:7501-7505. |
Peng and Marians, 1993, “Escherichia coli Topoisomerase IV”, J. Biol. Chem. 268:24481-24490. |
Pruss et al., 1986, “Effects of DNA Gyrase Inhibitors in Escherichia coli Topoisomerase Mutants ”, J. Bacteriol. 168:276-282. |
Pruss et al., 1982, “Escherichia coli DNA Topisomerase I Mutants: Increased Supercoiling is Corrected by Mutations Near Gyrase Genes”, Cell 31:35-42. |
Raji et al., 1985, “Genetic Analysis of Mutations That Compensate for Loss of Escherichia coli DNA Topoisomerase I”, J. Bacteriol. 162:1173-1179. |
Reece and Maxwell, 1991, “Probing the Limits of the DNA Breakage-Reunion Domain of the Escherichia coli DNA Gyrase A Protein”, J. Biol Chem. 266:3540-3546. |
Sampson et al., 1989, “Identifications and Characterization of a New Gene of Escherichia coli K-12 Involved in Outer Membrane Permeability”, Genetics 122:491-501. |
Schmid and Sawitzke, 1993, “Multiple Bacterial Topoisomerases: Specialization or Redundancy?”, BioEssays 15:445-449. |
Taylor and Menzel, 1995, “The Creation of a Camptothecin-Sensitive Escherichia coli Based on the Expression of the Human Topoisomerase I”, Gene 167:69-74. |
Tse-Dinh and Beran-Steed, 1988, “Escherichia coli DNA Topoisomerase I is a Zinc Metalloprotein with Three Repetitive Zinc-Binding Domains”, J. Biol. Chem. 263:15857-15859. |
Vosberg, 1985, “DNA Topoisomerases: Enzymes that Control DNA Conformation”, Curr. Top. Microbiol. Immunol. 114:19-102. |
Wang, 1994, “DNA Topoismerases as Targets of Therapeutics: An Overview”, Adv. Pharmacol., vol. 29A, Liu, ed., Academic Press, pp. 1-19. |
Wang, 1987, “Recent Studies of DNA Topoisomerases”, Biochem. Biophys. Acta 909:1-9. |
Wang, 1985, “DNA Topoisomerases”, Annu, Rev. Biochem. 54:665-697. |
Flamm et al., 1995, “In vitro evaluation of ABT-719, a noval DNA gyrase inhibitor”, Antimicrobial Agents & Chemotherapy 39(4):964-970. |
Nakane et al., 1995, “In vitro antibacterial activity DU-6859a, a new fluoroquinolone”, Antimicrobial Agents & Chemotherapy 39(12):2822-2826. |